The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
 
Matthew I. Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Consulting or Advisory Role - Loxo/Lilly
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); G1 Therapeutics (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape
 
Peter H. O'Donnell
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Axiom Healthcare Strategies; Axiom Healthcare Strategies; Axiom Healthcare Strategies; Axiom Healthcare Strategies; CLD, Inc.; CLD, Inc.; CLD, Inc.; CLD, Inc.; Curio Science; Curio Science; Curio Science; Curio Science; EMD Serono; EMD Serono; EMD Serono; EMD Serono; FirstWord; FirstWord; FirstWord; FirstWord; Great Debates and Updates; Great Debates and Updates; Great Debates and Updates; Great Debates and Updates; Institute for Enquiring Minds; Institute for Enquiring Minds; Institute for Enquiring Minds; Institute for Enquiring Minds; IntrinsiQ; IntrinsiQ; IntrinsiQ; IntrinsiQ; ISMIE; ISMIE; ISMIE; ISMIE; MedLearning Group; MedLearning Group; MedLearning Group; MedLearning Group; Merck; Merck; Merck; Merck; MJH Life Sciences; MJH Life Sciences; MJH Life Sciences; MJH Life Sciences; NAMCP; NAMCP; NAMCP; NAMCP; Peerview; Peerview; Peerview; Peerview; Pfizer; Pfizer; Pfizer; Pfizer; Research to Practice; Research to Practice; Research to Practice; Research to Practice; Seagen; Seagen; Seagen; Seagen; Vaniam Group; Vaniam Group; Vaniam Group; Vaniam Group
Research Funding - Acerta Pharma (Inst); Acerta Pharma (Inst); Acerta Pharma (Inst); Acerta Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Expert Testimony - Oregon Health & Science University (OHSU); Oregon Health & Science University (OHSU); Oregon Health & Science University (OHSU); Oregon Health & Science University (OHSU)
Travel, Accommodations, Expenses - Curio Science; Curio Science; Curio Science; Curio Science
Other Relationship - Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; Dragonfly Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Janssen; Janssen; Janssen; Janssen; Nektar; Nektar; Nektar; Nektar; NIH; NIH; NIH; NIH
 
Christopher J. Hoimes
Honoraria - Seagen; Seagen; Seagen; Seagen
Consulting or Advisory Role - 2bPrecise; 2bPrecise; 2bPrecise; 2bPrecise; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Prometheus; Prometheus; Prometheus; Prometheus; Seagen; Seagen; Seagen; Seagen
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Seagen; Seagen; Seagen; Seagen
Research Funding - Alkermes (Inst); Alkermes (Inst); Alkermes (Inst); Alkermes (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Dynavax Technologies (Inst); Dynavax Technologies (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); NeoImmuneTech (Inst); NeoImmuneTech (Inst); NeoImmuneTech (Inst); NeoImmuneTech (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst); 2bPrecise (Inst); 2bPrecise (Inst); 2bPrecise (Inst)
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Bellicum Pharmaceuticals; Bellicum Pharmaceuticals; Bellicum Pharmaceuticals; TYME; TYME; TYME; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Expert Testimony - Celgene; Celgene; Celgene; Celgene; sanofi; sanofi; sanofi; sanofi
 
Thomas W. Flaig
Leadership - Aurora Oncology; Aurora Oncology; Aurora Oncology; Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology; Aurora Oncology; Aurora Oncology; Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Seagen; Seagen; Seagen; Seagen
Research Funding - Agensys; Agensys; Agensys; Agensys; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; astrazeneca/MedImmune; astrazeneca/MedImmune; astrazeneca/MedImmune; astrazeneca/MedImmune; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Dendreon; Dendreon; Dendreon; Exelixis; Exelixis; Exelixis; Exelixis; GTx; GTx; GTx; GTx; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; La Roche-Posay; La Roche-Posay; La Roche-Posay; La Roche-Posay; Lilly; Lilly; Lilly; Lilly; Medivation; Medivation; Medivation; Medivation; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Sotio; Sotio; Sotio; Sotio; Tokai Pharmaceuticals; Tokai Pharmaceuticals; Tokai Pharmaceuticals; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Helen H Moon
Honoraria - EMD Serono; EMD Serono; EMD Serono; EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Apollomics (Inst); Apollomics (Inst); Apollomics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); HUYA Bioscience International (Inst); HUYA Bioscience International (Inst); HUYA Bioscience International (Inst); HUYA Bioscience International (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Prometheus; Prometheus; Prometheus; Prometheus; Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
 
Terence W. Friedlander
Leadership - Med BioGene; Med BioGene; Med BioGene; Med BioGene
Honoraria - Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; EMD Serono; EMD Serono; EMD Serono; EMD Serono
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Basilea; Basilea; Basilea; Basilea; Dava Oncology; Dava Oncology; Dava Oncology; Dava Oncology; Dendreon; Dendreon; Dendreon; Dendreon; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Merck; Merck; Merck; Merck
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen; Janssen; Janssen; Janssen; Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics
 
Nataliya Mar
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Aveo; Aveo; Aveo; Aveo; Eisai; Eisai; Eisai; Eisai; Seagen; Seagen; Seagen; Seagen; Tempus; Tempus; Tempus; Tempus
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; Astellas Medivation; Astellas Medivation; Astellas Medivation; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Caris Life Sciences; Caris Life Sciences; Caris Life Sciences; Caris Life Sciences; Dendreon; Dendreon; Dendreon; Dendreon; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Janssen; Janssen; Janssen; Merck; Merck; Merck; Merck; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi; Sorrento Therapeutics; Sorrento Therapeutics; Sorrento Therapeutics; Sorrento Therapeutics; Tempus; Tempus; Tempus; Tempus; Vividion Therapeutics; Vividion Therapeutics; Vividion Therapeutics; Vividion Therapeutics
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Tempus (Inst); Tempus (Inst); Tempus (Inst); Tempus (Inst)
 
Sandy Srinivas
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Seagen; Seagen; Seagen; Seagen
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst)
Other Relationship - Pfizer; Pfizer; Pfizer; Pfizer
 
Gwenaelle Gravis
Consulting or Advisory Role - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BMS (Inst); BMS (Inst); BMS (Inst); BMS (Inst); IPSEN (Inst); IPSEN (Inst); IPSEN (Inst); IPSEN (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Merck/Pfizer (Inst); Merck/Pfizer (Inst); Merck/Pfizer (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst)
Speakers' Bureau - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); BMS (Inst); BMS (Inst); BMS (Inst); BMS (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst); Sanofi/Aventis (Inst)
Research Funding - BMS (Inst); BMS (Inst); BMS (Inst); BMS (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi
 
Chethan Ramamurthy
Consulting or Advisory Role - Seagen; Seagen; Seagen; Seagen
Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Manojkumar Bupathi
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer
 
Sergio Bracarda
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma
 
Phoebe Wright
Employment - Seagen; Seagen; Seagen; Seagen
Stock and Other Ownership Interests - Seagen; Seagen; Seagen; Seagen
 
Anne-Sophie Carret
Employment - Seagen; Seagen; Seagen; Seagen
Stock and Other Ownership Interests - Seagen; Seagen; Seagen; Seagen
Honoraria - Seagen; Seagen; Seagen; Seagen
Travel, Accommodations, Expenses - Seagen; Seagen; Seagen; Seagen
 
Yao Yu
Employment - Seagen; Seagen; Seagen; Seagen
Stock and Other Ownership Interests - Seagen; Seagen; Seagen; Seagen
 
Tara Matsuda
Employment - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma
 
Ritesh S. Kataria
Employment - Merck; Merck; Merck; Merck
Stock and Other Ownership Interests - Merck; Merck; Merck; Merck
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Medscape; Medscape; Medscape; Medscape; MJH Life Sciences; MJH Life Sciences; MJH Life Sciences; MJH Life Sciences; Peerview; Peerview; Peerview; Peerview; Pfizer; Pfizer; Pfizer; Pfizer; Physicans' Education Resource; Physicans' Education Resource; Physicans' Education Resource; Physicans' Education Resource; Research To Practice; Research To Practice; Research To Practice; Research To Practice; UpToDate; UpToDate; UpToDate; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Alligator Bioscience; Alligator Bioscience; Alligator Bioscience; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; BioClin Therapeutics; BioClin Therapeutics; BioClin Therapeutics; BioClin Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Hengrui Pharmaceutical; Hengrui Pharmaceutical; Hengrui Pharmaceutical; Hengrui Pharmaceutical; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Imvax; Imvax; Imvax; Imvax; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Seagen; Seagen; Seagen; Seagen; Tyra Biosciences; Tyra Biosciences; Tyra Biosciences; Tyra Biosciences
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst); Predictor of platinum sensitivity (Inst); Predictor of platinum sensitivity (Inst); Predictor of platinum sensitivity (Inst)